Class / Patent application number | Description | Number of patent applications / Date published |
514217080 | The additional hetero ring is five-membered and contains nitrogen | 86 |
20080269200 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors - Indole carboxamide compounds of Formula (I): | 10-30-2008 |
20080312214 | Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme - Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I): | 12-18-2008 |
20080318933 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders - The present invention relates to novel indole derivatives such as compounds of the formula (I): | 12-25-2008 |
20090023708 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses - The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals. | 01-22-2009 |
20090054407 | Nitrogen-containing heterocyclic compound - The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): | 02-26-2009 |
20090137559 | BAZEDOXIFENE ASCORBATE - The present invention is directed to bazedoxifene ascorbate, compositions containing the same, dispersions thereof, preparations thereof, and uses thereof. | 05-28-2009 |
20090176764 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS - The present invention relates to new 2-Phenyl- | 07-09-2009 |
20100016290 | AMORPHOUS POLYMORPH OF BAZEDOXIFENE ACETATE - The invention provides a novel polymorphic form C of bazedoxifene acetate, methods of preparing the polymorphic form, and compositions and methods of treatment using the polymorphic form. | 01-21-2010 |
20100035862 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF - The invention relates to aza-cyclic-indole-2-carboxamide derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions. | 02-11-2010 |
20100120749 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to tetrahydroindole derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). | 05-13-2010 |
20100280009 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention is directed to 3,4-substituted pyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved. | 11-04-2010 |
20100292219 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION - The present invention provides tertiary amine substituted peptides of Formula (I) useful as inhibitors of HCV replication. The variables R and R | 11-18-2010 |
20100305105 | PHENYLSULFOXYOXAZOLE COMPOUND INHIBITORS OF UREA TRANSPORTERS - Provided herein are small molecule compounds that alter the transport activity of solute transporters, particularly urea transporters. The compounds described herein belong to the phenylsulfoxyoxazole, phenylsulfoxyimidazole, phenylsulfoxythiazole class of compounds. The compounds described herein are useful for increasing solute clearance in states of fluid overload and for treating cardiovascular, renal, and metabolic diseases, disorders, and conditions. Methods for identifying and using these agents that inhibit urea transporters are described herein. | 12-02-2010 |
20110021504 | POLYMORPHIC FORM D OF BAZEDOXIFENE ACETATE AND METHODS OF PREPARING SAME - The present disclosure relates to polymorphic Form D of bazedoxifene acetate, pharmaceutical compositions and methods of treatment using the same, and methods of preparing the same. | 01-27-2011 |
20110028454 | DEUTERIUM-ENRICHED BAZEDOXIFENE - The present application describes deuterium-enriched bazedoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 02-03-2011 |
20110065685 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS - The present invention provides novel compounds of Formula (I) | 03-17-2011 |
20110212947 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY - The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia. | 09-01-2011 |
20110312945 | CRTH2 MODULATORS - Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by formula I | 12-22-2011 |
20120232063 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria - The present invention relates to methods of treating a subject with malaria comprising administering a 2-aminoindole compound represented by Formula: (I)—The values and preferred values of the variables in Structural Formula I are defined herein. | 09-13-2012 |
20120245147 | INHIBITORS OF THAPSIGARGIN-INDUCED CELL DEATH - Methods for screening for inhibitors of endoplasmic reticulum (ER) stress are provided. These methods involve the addition of thapsigargin, which induces ER stress, and a test agent to mammalian cells in multi-well plates. Cell survival can be readily monitored by measuring intracellular ATP content using a bioluminescent reagent. Screening a commercially available library of 50,000 compounds led to the identification of 93 hit compounds that were subjected to secondary assays to confirm their ability to rescue cells from thapsigargin-induced cell death. | 09-27-2012 |
20130217679 | Compositions and Methods for Treatment of Neurodegenerative Disease - Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 08-22-2013 |
20140051687 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY - The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia. | 02-20-2014 |
20140296213 | NEW POLYMORPH - The invention provides a new polymorph of 1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzyl-carbamoyl)-L-proline-N,N-dimethylamide, pharmaceutical compositions containing it and its use in therapy. | 10-02-2014 |
20150031680 | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof - The present invention relates to the long-term administration of a selective estrogen receptor modulator (SERM) with a short half-life for the treatment of a variety of estrogen receptor-mediated conditions. The SERM may be administered at a concentration at or below that of a SERM with a long half-life in order to achieve an equivalent therapeutic effect. | 01-29-2015 |
20150080381 | METHODS OF TREATING ALOPECIA AND ACNE - Method of treating alopecia and acne with are disclosed. The compounds fall within described by formula I or II: | 03-19-2015 |
20160038506 | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof - The present invention relates to the long-term administration of a selective estrogen receptor modulator (SERM) with a short half-life for the treatment of a variety of estrogen receptor-mediated conditions. The SERM may be administered at a concentration at or below that of a SERM with a long half-life in order to achieve an equivalent therapeutic effect. | 02-11-2016 |
20160152605 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | 06-02-2016 |
20180022767 | Compounds for Treatment of Complement Mediated Disorders | 01-25-2018 |
514217090 | Plural ring hetero atoms in the additional hetero ring | 58 |
20080269201 | Azepane- or Azocane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments - The present invention relates to Azepane- or Azocane-substituted substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals | 10-30-2008 |
20090005364 | Azole Derivatives With Antimuscarinic Activity - The present invention relates to compounds of formula (I) wherein R1, R2, x, X, Y and B are as defined in the description for the treatment of muscarinic acetylcholine receptor mediated diseases, in particular M3 muscarinic receptor mediated diseases. | 01-01-2009 |
20090023709 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase - Provided herein are compounds of the formula (I): | 01-22-2009 |
20090042864 | PYRAZOLE COMPOUNDS -
This invention relates to pyrazole compounds of formula (I) shown below:
| 02-12-2009 |
20090137560 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR - The present invention relates to compounds of formula (I), | 05-28-2009 |
20090143364 | CHIRAL CIS-IMIDAZOLINES - and the pharmaceutically acceptable salts and esters thereof, wherein X | 06-04-2009 |
20090156582 | Pyrazole Compound - The present invention provides a pyrazole compound represented by the formula (I): | 06-18-2009 |
20090170832 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY - Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. | 07-02-2009 |
20090170833 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to the novel derivatives of formula (I) in which | 07-02-2009 |
20090270372 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS - A subject of the present Application is novel derivatives of benzimidazole and imidazopyridine which have a good affinity for certain sub-types of melanocortin receptors, in particular the MC4 receptors. They are particularly useful for treating pathological conditions and diseases in which one or more melanocortin receptors are involved. The invention also relates to pharmaceutical compositions containing said products. | 10-29-2009 |
20100004224 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS - The invention relates to the use of compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,4-triazole derivatives of formula (I) to processes of preparation of such compounds and to pharmaceutical compositions comprising them. | 01-07-2010 |
20100022517 | OPHTHALMIC FORMULATION OF RHO KINASE INHIBITOR COMPOUND - The present invention relates to an aqueous pharmaceutical formulation comprising at least one inhibitor of Rho-associated protein kinase (ROCK). The aqueous pharmaceutical formulation comprises 0.01-0.4% w/v of ROCK inhibitor(s), a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 220-360 mOsm/kG, at a pH between 6.3 to 7.8, wherein the ROCK inhibitor, the surfactant, and the tonicity agent are compatible in the formulation. The aqueous ophthalmic formulations of this invention have an increased ocular bioavailability and/or aqueous humor concentrations without a concomitant increase in systemic concentrations. The present invention further provides a method of reducing intraocular pressure, particularly a method of treating glaucoma, by administering the aqueous pharmaceutical formulation to a subject. | 01-28-2010 |
20100069364 | SUBSTITUTED PYRAZOLINE COMPOUNDS WITH ACAT INHIBITION ACTIVITY, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia. | 03-18-2010 |
20100105663 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS - The invention relates to substituted indazoles and methods for production thereof and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, especially of cardiovascular diseases, preferably of thromboembolic diseases. | 04-29-2010 |
20100125064 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases - The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula I, | 05-20-2010 |
20100204210 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS - This invention relates to methods of treating pulmonary diseases in patients that beta adrenergic receptor agonist therapy is not effective. The method comprises the steps of: identifying a patient who suffers from a pulmonary disease and has reduced responsiveness to treatment with one or more beta adrenergic receptor agonists, and administering to the patient an effective amount of a Rho kinase inhibitor compound, wherein said pulmonary disease is selected from the group consisting of: asthma, chronic obstructive pulmonary disease, respiratory tract illness caused by respiratory syncytial virus infection such as RSV-induced wheezing, airway hyperreactivity, or bronchiolitis, bronchiectasis, alpha-1-antitrypsin deficiency, lymphangioleiomyomatosis, cystic fibrosis, bronchiolitis or wheezing caused by agents other than respiratory syncytial virus, chronic bronchitis, and occupational lung diseases. | 08-12-2010 |
20100267698 | Benzimidazole and Pyridylimidazole Derivatives - This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I | 10-21-2010 |
20110003797 | HEXAHYDROCYCLOPENTYL[f]INDAZOLE CARBOXAMIDES AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS - The present invention is directed to hexahydrocyclopentyl[f]imidazole carboxamides and derivatives thereof as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included. | 01-06-2011 |
20110015183 | SUBSTITUTED PYRAZOLE SIGMA RECEPTOR ANTAGONISTS - The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to pyrazole derivatives of formula I | 01-20-2011 |
20110082131 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS - Methods of using triazole derivatives in treating diseases or conditions associated with Axl catalytic activity are disclosed. | 04-07-2011 |
20110160188 | PARAMYXOVIRUS FAMILY INHIBITORS AND METHODS OF USE THEREOF - Embodiments of the present disclosure include methods for identifying a compound or compounds useful as therapeutic agents in the treatment of paramyxovirus infections, compounds for the treatment of measles, and high throughput screening methods for identifying compounds capable of inhibiting the proliferation of a paramyxovirus. | 06-30-2011 |
20110207719 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof - A series of novel anthra[1,2-d]imidazole-6,11-dione derivatives, and the preparation method and application of said derivatives, wherein said application includes a pharmaceutical composition containing said derivatives for treating cancer, and said application involves effects of said derivatives for inhibiting telomerase activity, inhibiting the growth of cancer cell, treating cancer and the like. | 08-25-2011 |
20110281848 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR - The present invention relates to compounds of formula (I), | 11-17-2011 |
20120004211 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS - The invention relates to the use of compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,4-triazole derivatives of formula I | 01-05-2012 |
20120010195 | IMIDAZOLE DERIVATIVES - The present invention relates to novel imidazole derivatives of formula (I) having microbiocidal, in particular fungicidal, activity, to processes for their preparation and intermediates used in their preparation, to agrochemical compositions comprising them and to the use in agriculture or horticulture for controlling or preventing infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, preferably fungi. | 01-12-2012 |
20120065191 | PHARMACEUTICAL COMPOUNDS - The invention relates to compounds and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAAH), the use of the compounds in therapy and, in particular, for treating or preventing conditions whose development or symptoms are linked to substrates of the FAAH enzyme, and methods of treatment or prevention using the compounds and compositions. | 03-15-2012 |
20120088751 | PHARMACEUTICAL COMPOUNDS - Tricyclic pyrazole derivatives of the following formula (I) having affinity for the cannabinoidergic CB1 and/or CB2 receptors: | 04-12-2012 |
20120088752 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF - Heterocyclic compounds that modulate the hedgehog signaling pathway, pharmaceutical composition thereof and their therapeutic applications. | 04-12-2012 |
20120277217 | Imidazole Derivatives as IDO Inhibitors - Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease. | 11-01-2012 |
20130158014 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS - This invention is directed to methods of preventing or treating diseases or conditions associated with alterations in cellular integrity including alterations in endothelial permeability, excessive cell proliferation or tissue remodeling. Particularly, this invention is directed to methods of treating diabetic nephropathy, malaria, or cancer. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel rho kinase inhibitor compound to treat the disease. | 06-20-2013 |
20140051688 | PYRROLOPYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 02-20-2014 |
20140171420 | DIAZOLE LACTAMS - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists. | 06-19-2014 |
20150031681 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE - A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I): | 01-29-2015 |
20160024052 | BENZIMIDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF - Provided herein are compounds of the formulas (I) and (II): | 01-28-2016 |
20160024056 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF - Provided herein are compounds of the formula (I): | 01-28-2016 |
20160024057 | INDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF - Provided herein are compounds of the formulas (I) and (II): | 01-28-2016 |
514217100 | Chalcogen is one of the ring hetero atoms | 22 |
20080255094 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR - The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. | 10-16-2008 |
20090023707 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS - The present invention provides a compound of formula I: | 01-22-2009 |
20090062259 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists - The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta adrenoreceptor agonists. | 03-05-2009 |
20090075979 | CETP Inhibitors - Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R | 03-19-2009 |
20090215749 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR - The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. | 08-27-2009 |
20090281084 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS - The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. | 11-12-2009 |
20090298811 | BENZIMIDAZOLONE DERIVATIVES - This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts thereof, wherein: A, B, R | 12-03-2009 |
20100152166 | COMPOUNDS AND METHODS FOR MODULATING FXR - Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia. | 06-17-2010 |
20100222328 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES - The invention relates to selected 2-cyclopropyl-thiazole derivatives of the formula (I) wherein B, Y and R1 are as described in the description; to salts and especially pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists. | 09-02-2010 |
20100305104 | Oxadiazole Diaryl Compounds - The invention relates to compounds of formula (I): | 12-02-2010 |
20110195955 | HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS - A compound useful for treating subjects in need of therapy involving sigma receptors or for alleviation of affects resulting from drug abuse having the general formula I | 08-11-2011 |
20120046273 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING - Muscarinic agonists, which are useful for stimulating muscarinic receptors and treating cognitive disorders, are provided. Methods of synthesizing such agonists also are provided. Also provided are compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. Also provided are methods of treating animals such as humans by administering such compositions. | 02-23-2012 |
20120108571 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS - The present invention relates to compounds of Formula (I), | 05-03-2012 |
20120264744 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF - A series of oxazole and thiazole compounds are shown herein to be small molecule inhibitors of the Wnt pathway that specifically target the activity of the stabilized pool of β-catenin. Oxazole and thiazole compounds are disclosed that have a formula represented by the following: | 10-18-2012 |
20130109675 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | 05-02-2013 |
20130109676 | Oxadiazole Diaryl Compounds | 05-02-2013 |
20130137678 | Antiviral Compounds and Uses Thereof - Described herein are Compounds, compositions comprising such Compounds, and the use of such Compounds and compositions as anti-viral agents. In one aspect, provided herein are methods of inhibiting viral replication using Compounds described herein or compositions thereof. In another aspect, provided herein are methods for preventing a symptom of a viral infection using a Compound, or a composition thereof. In another aspect, provided herein are methods of treating and/or managing viral infection using a compound or a composition thereof. | 05-30-2013 |
20130184258 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels - The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 07-18-2013 |
20130261108 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS - The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR). | 10-03-2013 |
20130338144 | uPAR-uPA INTERACTION INHIBITORS AND METHODS FOR TREATING CANCER - The invention described herein pertains to compounds, compositions and formulations comprising the compounds, and methods for use of the compounds, compositions and/or formulations in the treatment of diseases responsive to the inhibition of uPAR-uPA interactions, such as cancer. | 12-19-2013 |
20150051193 | PI-kinase Inhibitors with Broad Spectrum Anti-Infective Activity - Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like. | 02-19-2015 |
20160194314 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | 07-07-2016 |